Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 16/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483762 | 1.00 | TACR1 (0.62) | TACR1DPP4DPP8DPP9KCNH2 | |
| SCHEMBL6497500 | 0.88 | TACR1 (0.62) | TACR1KCNH2SLC18A3 | |
| SCHEMBL6497494 | 0.88 | TACR1 (0.62) | TACR1KCNH2SLC18A3 | |
| SCHEMBL5764286 | 0.84 | TACR1 (0.54) | TACR1KCNH2SLC18A3 | |
| SCHEMBL5764289 | 0.84 | TACR1 (0.54) | TACR1KCNH2SLC18A3 | |
| SCHEMBL4562995 | 0.80 | DPP4 (0.69) | TACR1DPP4DPP8DPP9MAOA | |
| SCHEMBL14549651 | 0.79 | DPP4 (0.55) | TACR1DPP4DPP8DPP9KCNH2 | |
| SCHEMBL8179593 | 0.79 | DPP4 (0.71) | TACR1DPP4DPP8DPP9MAOA | |
| SCHEMBL4553580 | 0.79 | DPP4 (0.71) | TACR1DPP4DPP8DPP9MAOA | |
| Hydrochloric Acid SCHEMBL14482711 | 0.78 | DPP4 (0.54) | TACR1DPP4DPP8DPP9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953792-B2 | Cyclohexyl derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20030225059-A1 | Cyclohexyl derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225059-A1 | Cyclohexyl derivatives and their use as therapeutic agents | CNR2, CNR1, HRH2 | TACR1 389/4885DPP4 2183/4885DPP8 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.